German Biotech's Selective Approach Unlocks New Heart Failure Funding

Jan de Vries · 2026-08-28

A fresh player has entered the European biotech arena with a focused mission and fresh capital. Revier Therapeutics, based in Heidelberg, Germany, has officially launched and closed a significant Seed financing round worth approximately $6.5 million. This isn't just another startup story—it's about a company aiming to reshape treatment for some of the most common and challenging heart conditions out there. Their target? Cardiometabolic diseases, a broad category that includes heart failure and atherosclerotic cardiovascular disease (ASCVD). Millions live with these conditions, and while medicine has come a long way, targeted treatment options are still frustratingly limited for many patients. ### The Science Behind the Strategy So, what's Revier doing differently? Their entire approach hinges on a precise biological target: class IIa histone deacetylases, or HDACs for short. Think of HDACs as enzymes that play a key role in how our genes are regulated. When they go awry, they can drive disease. Here’s the crucial part. Earlier, first-generation HDAC inhibitors were like using a sledgehammer—they broadly targeted multiple HDAC classes, which often led to serious side effects that limited how much medicine a patient could tolerate. Revier’s science is designed to be more like a scalpel. - Their orally available small molecules are built to selectively inhibit only the class IIa HDACs. - This precision aims to stop the disease-driving activity while preserving the essential, healthy functions of these enzymes and others. - The goal is a therapy that’s both powerful and safer, a combination that’s been elusive. "We believe the next generation of cardiometabolic medicines needs to address the underlying disease-driving biology," said Prof. Eva van Rooij, PhD, the company's CEO and co-founder. She frames their mission as translating deep scientific potential into a pipeline of novel therapies that offer long-term solutions, not just temporary relief. ### The Backing and The Road Ahead The $6.5 million seed round was led by the KHAN Technology Transfer Fund II, with support from High-Tech Gründerfonds (HTGF), VORNvc, and private investors. This coalition of regional and specialized biotech investors signals strong belief in the team and the science. Michael Hamacher of KHAN highlighted the potential, noting Revier's strategy could "unlock the therapeutic promise of HDAC biology" by overcoming the limitations of older approaches. It’s that promise of a true disease-modifying medicine—one that changes the course of the illness itself—that’s so compelling. With the new capital, Revier plans to push forward its two lead programs. The first focuses on heart failure with preserved ejection fraction (HFpEF), a particularly tough-to-treat form of heart failure. The second targets ASCVD. The funding will fuel preclinical development and help build out the team needed to eventually advance these therapies toward clinical trials. It’s a story of targeted science meeting strategic investment. For professionals watching the European startup and biotech incorporation landscape, Revier Therapeutics exemplifies the deep, research-driven innovation emerging from Germany’s ecosystem. Their journey from lab concept to a company with a clear path to the clinic is one to watch.